A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer
A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer
复制标题
在已切除的胰腺癌患者中进行吉西他滨辅助化疗与观察的随机、前瞻性、多中心 III 期试验
DOI：
10.1200/jco.2005.23.16_suppl.lba4013
复制
发表时间：
2005
影响因子：
45.3
通讯作者：
H. Riess
中科院分区：
文献类型：
--
作者：
P. Neuhaus;H. Oettle;S. Post;K. Gellert;K. Ridwelski;H. Schramm;C. Zülke;G. Fahlke;J. Langrehr;H. Riess
LBA4013 Background: Chemotherapy with Gemcitabine 1 g/m2 given on d 1, 8, 15 every four weeks is standard therapy in inoperable pancreatic cancer. The value of adjuvant therapy has not been clearly defined and no data on randomised trials with Gemcitabine in the adjuvant setting is available. Methods: This study was designed to evaluate the efficacy and toxicity of Gemcitabine in patients with resectable pancreatic cancer. Within 6 weeks after operation, patients were randomised to receive Gemcitabine or observation after stratification for positive or negative resection margins, nodal tumor involvement and tumor stage. Gemcitabine was administered at a dosage of 1g/m2 days 1, 8 and 15 every 4 weeks for 6 months. Patients in the observation arm received no specific postoperative treatment. Primary endpoint was disease free survival (DFS), secondary endpoints included overall survival (OS) and side effects in both groups. The study was powered to detect a significant difference with 90% probability at a si...
